EMEA-002750-PIP01-19

Key facts

Active substance
surufatinib
Therapeutic area
Oncology
Decision number
P/0142/2021
PIP number
EMEA-002750-PIP01-19
Pharmaceutical form(s)
  • Capsule, hard
  • Powder for oral suspension
Condition(s) / indication(s)
  • Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
  • Treatment of malignant neoplasms of haematopoietic and lymphoid tissue
Route(s) of administration
Oral use
Contact for public enquiries
Hutchison MediPharma Ltd
E-mail: marjoh@hmplglobal.com
Tel: +358 408425802
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating